|
|
 |
|
Applications
|
|
|
At Miltenyi Biotec everything is geared towards synergy
In particular, microarray-based analysis of nucleic acids has become a valuable tool for molecular cell characterization in basic research.
For the translation of these research findings from bench to bedside it is a detailed understanding of disease biology that allows for the identification of biomarkers.
Biomarker discovery represents a key element of all diagnostic, toxicogenomic and pharmacogenomic research studies.
The sensitivity and specificity of microarray-derived profiles is of great importance for all these clinical applications. Both can be significantly increased by reducing sample complexity via magnetic cell separation (MACS® Technology); we call the synergy of MACS and genomic analysis ‘MACS®-4-omics’.
|
|
|
Specific cells for specific answers
Microarray-based analysis of nucleic acids has become a valuable tool for molecular cell characterization in basic research. Usually, it is the access, the quality and the quantity of starting material that limits reliable gene or microRNA expression profiling analysis.
Next to a first-class genomic service, Miltenyi Biotec also provides comprehensive solutions for the separation of distinct cell populations from samples such as tissue, blood, bone marrow, or other bodily fluids. The synergy of MACS Magnetic Cell Separation and genomic analysis is called ‘MACS®-4-omics’.
Please click here to better understand how MACS-4-omics increases the sensitivity and specificity of microarray-based genomic analysis, e.g., for cell characterization.
Miltenyi Biotec’s long expertise in both microarray-based genomic analysis and magnetic cell separation is of great value to basic and clinical research scientists looking to plan, execute, analyse, and validate the results of gene and microRNA expression studies, as well as array-CGH analysis.
Experts in the field of immunology have successfully made use of our expertise, resulting in several high impact publications, such as Auffray et al. (Science, 2007).
Use our contact form to get in touch and to discuss your projects with our experts.
|
|
|
Defining disease
Microarray-based analysis of inherited and acquired genomic variations, as well as transcriptional changes, allows for a deeper understanding of initiation and progression of disease.
Unravelling the biology of complex diseases, such as cancer, is a prerequisite for the development of new therapeutic interventions. The wealth of validated data sets that come from microarray analysis likely holds the information necessary to develop such approaches.
Several microarray studies have shown how valuable this technology is for the clear identification and characterization of disease, as initially described by Golub et al. (Science, 1999) and were further proven by numerous other studies, several of them based on data from our genomic service department (Wenzel et al., Int. J. Cancer, 2008).
Use our contact form to get in touch and to discuss your projects with our experts.
|
|
|
Advancing biomarker discovery
In order to reduce the attrition rate in drug development, a global trend toward personalized medicine and companion diagnostics can be observed.
Key elements for these strategies are robust and validated biomarkers for predictive, prognostic and diagnostic purposes.
Miltenyi Biotec’s Genomic Service Team has gained substantial experience through the successful execution of several large-scale microarray projects carried out together with industrial and clinical partners, e.g., within different EU consortia, such as Indices of tolerance (IOT, Sagoo et al. 2010).
Because of this expertise, our Genomic Service Team is the ideal outsourcing partner for your biomarker research.
Use our contact form to get in touch and to discuss your projects with our experts.
|
|
|
MACS®-4-omics - the significance of disease-related signatures!
A prerequisite for all multi-omics analyses is access to appropriate starting materials.
Clear definition and homogeneity of samples is mandatory for successful translation of microarray-based analysis from research into clinic.
Most studies published to date have used heterogeneous populations of blood cells, either total leukocytes or Ficoll-purified peripheral blood mononuclear cells. As a consequence, many of the signatures that have been reported may be attributable to differences in the relative abundance of individual leukocyte populations. Reducing the complexity of those samples can significantly improve the data output. If whole blood represents your preferred starting material, the isolation of cells of interest can easily be achieved with Miltenyi Biotec’s Whole Blood MicroBeads
(Palmer et al., BMC Genomic, 2006) (Lyons et al., BMC Genomic, 2007) (Lyons et al., Ann Rheum Dis., 2010).
Miltenyi Biotec provides a promising strategy, called MACS®-4-omics, which helps to circumvent problems with heterogeneous samples. MACS®-4-omics describes the synergy of magnetic cell separation - MACS® Technology - and genomic analysis. As market leader in magnetic cell separation, we know how to isolate virtually any cell type from any source. Even solid tissue doesn’t stop us from isolating distinct cell populations, as our gentleMACS™ Dissociator allows for the gentle homogenization of tissue for subsequent magnetic cell separation.
The synergy of MACS Technology and genomic analysis—MACS®-4-omics—is an ideal tool to accelerate and increase the success rate of drug development and clinical studies.
Use our contact form to get in touch and to discuss your projects with our experts.
|
|
|
|
